Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.54 |
| ▸ | FABP7 | O15540 | 2/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CASP3 | P42574 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29608029 | 1.00 | KMT2A (0.55) | KMT2APOLBFABP5FABP7EPHX2 | |
| SCHEMBL10119030 | 0.88 | KMT2A (0.51) | KMT2APOLBFABP5FABP7EPHX2 | |
| SCHEMBL16070810 | 0.88 | EPHX2 (0.49) | KMT2APOLBFABP5FABP7EPHX2 | |
| SCHEMBL13826222 | 0.87 | KMT2A (0.48) | KMT2APOLBFABP5FABP7EPHX2 | |
| SCHEMBL20759187 | 0.87 | EPHX2 (0.45) | KMT2APOLBFABP5FABP7EPHX2 | |
| SCHEMBL20759381 | 0.87 | FABP5 (0.45) | KMT2APOLBFABP5FABP7EPHX2 | |
| SCHEMBL29703842 | 0.86 | KMT2A (0.47) | KMT2APOLBFABP5FABP7EPHX2 | |
| SCHEMBL17742679 | 0.85 | POLB (0.44) | KMT2APOLBFABP5FABP7EPHX2 | |
| SCHEMBL15981181 | 0.85 | KMT2A (0.58) | KMT2APOLBFABP5FABP7EPHX2 | |
| SCHEMBL44676 | 0.85 | KMT2A (0.58) | KMT2APOLBFABP5FABP7EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2236 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024151672-A1 | DIRECTED BIOSYNTHESIS OF MODIFIED ANTHRAQUINONE-FUSED ENEDIYNES AS POTENTIAL CANCER THERAPEUTICS | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-07-18 | — | — | WO | disclosed |
| US-12037405-B2 | Anti-CD70 antibody drug conjugates | AMBRX, INC. | 2024-07-16 | — | — | US | disclosed |
| US-12037405-B2 | Anti-CD70 antibody drug conjugates | AMBRX, INC. | 2024-07-16 | — | — | US | disclosed |
| US-12037357-B2 | Compounds for activating invariant natural killer T-cells and methods of use in eliminating inflammatory senescent cells | DECIDUOUS THERAPEUTICS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| WO-2024145273-A2 | N-MYRISTOYLTRANSFERASE INHIBITORS AND METHODS OF USE | SEATTLE CHILDREN'S HOSPITAL (D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE) (US) | 2024-07-04 | — | — | WO | disclosed |
| WO-2024137502-A2 | PNU ANTHRACYCLINE-DERIVED LINKER-PAYLOADS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-06-27 | — | — | WO | disclosed |
| US-20240209363-A1 | OLIGONUCLEOTIDES FOR TREATING EXPANDED REPEAT DISEASES | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2024-06-27 | — | — | US | disclosed |
| EP-3488870-B1 | ANTI-CD70 ANTIBODY DRUG CONJUGATES | AMBRX INC (US) | 2024-03-20 | — | — | EP | disclosed |
| US-20240067674-A1 | METHOD FOR LOADING AMINO ACID ON RESIN FOR SOLID-PHASE SYNTHESIS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2024-02-29 | — | — | US | disclosed |
| US-11911403-B2 | Antisense-induced exon exclusion in type VII collagen | SAREPTA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| WO-2004094461-A2 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-11-04 | — | — | WO | disclosed |
| US-20040210041-A1 | Multimeric proteins for use in the treatment and detection of cell proliferative disorders | ARBOGAST CHRISTOPHE (FR) | 2004-10-21 | — | — | US | disclosed |
| WO-2003033671-A2 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-04-24 | — | — | WO | disclosed |
| US-6359113-B1 | USING FUSED RING SYSTEM CONTAINING AT LEAST 4 AROMATIC RINGS, AND GROUP CONTAINING AT LEAST ONE CARBON ATOM WHICH IS CAPABLE OF BONDING TO A GROUP TO BE PROTECTED; SYNTHESIS, SEPARATION | RHODIA CHIMIE (FR) | 2002-03-19 | — | — | US | disclosed |
| EP-0920403-B1 | PROCESS FOR PREPARING CYCLOPENTADIENYL COMPOUNDS | BASELL TECHNOLOGY CO BV (NL) | 2002-01-30 | — | — | EP | disclosed |
| US-6162937-A | Process for preparing cyclopentadienyl compounds | MONTELL TECHNOLOGY COMPANY B.V. (NL) | 2000-12-19 | — | — | US | disclosed |
| CN-1226882-A | Process for preparing cyclopentadienyl compounds | MONTELL TECHNOLOGY COMPANY BV (NL) | 1999-08-25 | — | — | CN | disclosed |
| EP-0920403-A1 | PROCESS FOR PREPARING CYCLOPENTADIENYL COMPOUNDS | Montell Technology Company bv (NL) | 1999-06-09 | — | — | EP | disclosed |
| US-5869605-A | Protected compound comprising a protective group removably attached to a compound to be protected | RHONE-POULENCCHIMIE (FR) | 1999-02-09 | — | — | US | disclosed |
| WO-1998043931-A1 | PROCESS FOR PREPARING CYCLOPENTADIENYL COMPOUNDS | MONTELL TECHNOLOGY COMPANY B.V. (NL) | 1998-10-08 | — | — | WO | disclosed |